Hormone Therapy Options for Endometriosis — A Realistic Guide

Hormonal medical management is the cornerstone of long-term endometriosis care. This page explains the major classes of hormone therapy, what each does, who they suit, and their realistic trade-offs — so you can make informed choices alongside your specialist.

1. Combined oral contraceptive (COC)

The most commonly prescribed first-line. Combination of oestrogen + progestin, suppresses ovulation and reduces cyclical disease activity. Continuous use (skip the placebo week) is often preferred for endometriosis to suppress menstruation entirely. Pros: cheap, well-tolerated, contraception bonus. Cons: thrombosis risk in selected patients, not always sufficient for severe disease.

2. Progestin-only therapy

Norethisterone, dienogest, medroxyprogesterone acetate. Suppresses endometrium and ovulation. Continuous dienogest (Visanne) is well studied for endometriosis pain. Pros: avoids oestrogen, suitable for migraine-with-aura, thrombosis history, smoking over 35. Cons: irregular bleeding, mood effects, weight gain in some patients.

3. Levonorgestrel-releasing intrauterine system (Mirena)

Local progestin release directly to the uterus. Reduces menstrual bleeding by 90% within 6 months. Effective for endometriosis-related dysmenorrhoea, particularly with coexisting adenomyosis. Pros: 5–8 years effect, minimal systemic side effects. Cons: insertion discomfort, irregular bleeding initially, occasional expulsion.

4. GnRH agonists

Goserelin, leuprolide, triptorelin. Induce pseudomenopause by suppressing pituitary FSH/LH. Highly effective for severe pain and pre-surgical disease shrinkage. Pros: powerful suppression. Cons: menopausal side effects (hot flushes, mood, bone loss). Requires “add-back” therapy (low-dose oestrogen + progestin) for use beyond 6 months.

5. GnRH antagonists — the new class

Elagolix, relugolix combinations. Oral, rapid onset, dose-adjustable suppression. Lower-dose options preserve some ovarian function while reducing pain. Pros: oral, flexible dosing, less severe menopausal symptoms at lower doses. Cons: cost, newer (less long-term data), still some hypoestrogenic effects.

6. Selecting the right agent

First-line: COC continuous or Mirena IUS for most patients. Second-line: dienogest if COC contraindicated or insufficient. Third-line: GnRH antagonists or agonists with add-back for refractory pain. Patient factors (contraception need, age, comorbidities, side effect tolerance) drive choice. There is no single best agent — fit matters.

7. Hormonal therapy for fertility-seekers

When pregnancy is being sought, hormonal suppression is paused. Pre-pregnancy disease control reduces post-pregnancy recurrence risk. After delivery and breastfeeding, hormonal management often resumes to prevent recurrence and progression. Decisions integrate fertility timeline with disease severity.

8. Long-term considerations

Hormonal management is often lifelong (until menopause) for moderate-severe disease. Bone density monitoring with prolonged GnRH agonist use. Annual review of side effects, efficacy and quality of life. Switching agents is appropriate if current regimen is not working — there is no single “endometriosis pill”.